Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00571818
Other study ID # 0114-00-FB
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 1, 2000
Est. completion date June 1, 2010

Study information

Verified date October 2023
Source University of Nebraska
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to understand how the pancreas functions after transplantation and particularly why high blood sugar levels develop. It will also analyze the effect of the medicines used to prevent rejection on blood sugar levels. The hypothesis to be tested is that hyperglycemia more than six months after successful pancreas transplant results from a defect in insulin secretion, insulin resistance, or both.


Description:

Type I diabetes mellitus (DM1) is an autoimmune disease characterized by destruction of the insulin-secreting beta cells. Insulin replacement has been the cornerstone of therapy for patients with DM1. However, pancreas transplantation, utilizing the whole pancreas as a means to replace the destroyed beta cells, has become a therapeutic alternative. The goal of pancreas transplantation is the establishment of long-term euglycemia, thereby preventing or allowing for the repair of end-organ complications. Maintenance of the pancreas allograft over many years remains the goal in following pancreas transplant recipients over time. The onset of hyperglycemia less than one year after transplant is usually due to issues of surgical technique or acute rejection. However, the onset of hyperglycemia after one year of pancreas transplant is more problematic because the underlying causes are less clear and have been less well characterized. Currently, there is no protocol for definitively identifying the causes of hyperglycemia in pancreas transplant recipients over one year. This project will systematically characterize beta cell function and peripheral tissue response to insulin in patients who have received an earlier successful pancreas transplant who have developed hyperglycemia.


Recruitment information / eligibility

Status Completed
Enrollment 31
Est. completion date June 1, 2010
Est. primary completion date March 1, 2008
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 19 Years to 65 Years
Eligibility Inclusion Criteria: - Hyperglycemic pancreas transplant recipients: - ages 19-65 - received a pancreas transplant = 9 months previously - fasting glucose levels = 126 mg/dl - hemoglobin A1C > 1% above normal - Euglycemic pancreas transplant recipients: - ages 19-65 - received a pancreas transplant = 9 months previously - fasting glucose levels are < 126 mg/dl - normal HbA1C without taking any medications for the treatment of high blood sugars. - Euglycemic Kidney Transplant Recipients: - ages 19-65 - no prior diagnosis of diabetes - received a kidney transplant = 9 months previously - showing continued function - Euglycemic Healthy Control Subjects: - ages 19-65 - no diabetes or renal disease Exclusion Criteria: - Hyperglycemic pancreas transplant recipients: - chronic illnesses that would decrease insulin sensitivity ( - terminal illness - BMI > 30 kg/m2 - serum creatinine > 2 mg/dl - hemoglobin < 10 g/dl - an episode of acute rejection with the preceding 3 months of entry. - Euglycemic pancreas transplant recipients: - Exclusion criteria are the same as with hyperglycemic transplant patients. - no diagnosis of type 2 diabetes. - Euglycemic Kidney Transplant Recipients: - Exclusion criteria are the same as for euglycemic pancreas transplant recipients above. - Euglycemic Healthy Control Subjects: - chronic illnesses - medications known to affect glucose metabolism - a history of smoking - serum creatinine = 1.5 mg/dl - BMI > 30 kg/m2.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Oral glucose tolerance test
test done over 2 hours
IV Glucose Tolerance Test
Done over 4 hours

Locations

Country Name City State
United States University of Nebraska Medical Center Omaha Nebraska

Sponsors (1)

Lead Sponsor Collaborator
University of Nebraska

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluate beta cell secretion Evaluate beta cell secretion by oral glucose tolerance test (done over 2 hours) and IV Glucose Tolerance Test (done over 4 hours) 9 months post-transplant or at time of participation for controls
Primary Evaluate insulin sensitivity/glucose effectiveness Evaluate insulin sensitivity/glucose effectiveness by oral glucose tolerance test (done over 2 hours) and IV Glucose Tolerance Test (done over 4 hours) 9 months post-transplant or at time of participation for controls
See also
  Status Clinical Trial Phase
Completed NCT05594446 - Morphometric Study of the Legs and Feet of Diabetic Patients in Order to Collect Data Intended to be Used to Measure by Dynamometry the Pressures Exerted by Several Medical Compression Socks at the Level of the Forefoot
Completed NCT03975309 - DHS MIND Metabolomics
Completed NCT01855399 - Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes N/A
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Recruiting NCT04984226 - Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD Phase 2
Recruiting NCT05007990 - Caregiving Networks Across Disease Context and the Life Course
Active, not recruiting NCT04420936 - Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care for Our Program N/A
Recruiting NCT03549559 - Imaging Histone Deacetylase in the Heart N/A
Completed NCT04903496 - Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional Database
Completed NCT01437592 - Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects Phase 1
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT03390179 - Hyperglycemic Response and Steroid Administration After Surgery (DexGlySurgery)
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Recruiting NCT05294822 - Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes N/A
Completed NCT04427982 - Dance and Diabetes/Prediabetes Self-Management N/A
Completed NCT02356848 - STEP UP to Avert Amputation in Diabetes N/A
Completed NCT03292185 - A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects Phase 1
Active, not recruiting NCT05477368 - Examining the Feasibility of Prolonged Ketone Supplement Drink Consumption in Adults With Type 2 Diabetes N/A
Completed NCT04496401 - PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus Phase 4